Full Title: Stakeholder Opinions: HIV/ HBV Co-infection - More Potency, More Policy Introduction Long-term usage of HAART for the management of HIV has reduced mortality in the HIV-infected population. However, this has consequently led to an increase in the prevalence of chronic co-infections such as Hepatitis B (HBV). Currently, HBV prevalence exceeds that of HIV and is estimated at 2 billion infected individuals worldwide, accounting for approximately 5% of the world’s population. Scope - Key data and epidemiology of the seven major HIV therapeutic markets highlighting the HIV / HBV co-morbid population
- Overview of the limitations surrounding co-morbid management such as recognition of co infection, high-risk groups and lack of efficacious antivirals
- Analysis based on interviews with key opinion leaders in the major markets
Highlights Concurrent early diagnosis of both HIV and HBV disease states is pivotal to increasing the lifespan of this co-morbid population. Effective treatment is currently hampered by poor patient compliance, HAART hepatotoxicity and lack of comprehensive treatment guidelines. Lack of potency with current HBV therapeutics is an obvious gap in treating both mono and co-infected patients currently being addressed by companies such as Gilead and Idenix/Novartis. Commercial support for global implementation of HBV vaccination need not preclude a high volume/low cost business model for a new potent HBV antiviral. Reasons to Purchase - Effectively target this niche sector, through a complete understanding of the prevalence of the co-morbid population in the seven major markets
- Identify the most promising products in the HIV and HBV pipelines, and track how current players are seeking to optimize their market share
Pages: 89 Table of Contents Download TOC in PDF
Stakeholder Opinions Reports View all available Stakeholder Opinions Reports
|
